InvestorsHub Logo
Followers 21
Posts 2542
Boards Moderated 0
Alias Born 12/07/2013

Re: BioInvestor3 post# 383098

Wednesday, 07/13/2022 11:11:34 AM

Wednesday, July 13, 2022 11:11:34 AM

Post# of 426485
Unfortunately, the lesson that was taught here is you can't only look at the science.

If Someone would have said to me 5 years ago:

We have a new product for the Number one killer that will reduce events by 25% on top of current treatments.

I would have responded - If all that is true you have a block buster on your hands .

As we all know, that was true but Thero and Crew and now Mikhail have failed miserably in advancing this product. It is incompetence to the highest degree, an absolute failure to understand the business environment in which they were operating .

MY take away on this: DD not only requires an evaluation of the science it requires an evaluation of CEO capability and experience
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News